Current Limitations in the Treatment of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers

Current Medicinal Chemistry
Chiara Tonda-TuroValeria Chiono

Abstract

Alzheimer's and Parkinson's diseases are the most common neurodegenerative diseases worldwide and their incidence is increasing due to the aging population. At the moment, the available therapies are not disease modifying and have several limitations, some of which are discussed in this review. One of the main limitations of these treatments is the low concentration that drugs reach in the central nervous system after systemic administration. Indeed, the presence of biological barriers, particularly the blood-brain barrier (BBB), hinders the effective drug delivery to the brain, reducing the potential benefit coming from the administration of the medication. In this review, the mechanisms of transport across the BBB and new methods to improve drug passage across the BBB are discussed. These methods include non-invasive solutions such as intranasal and intravitreal administration, and the use of nanotechnology solutions based on polymeric carriers when the drug is intravenously injected, orally taken for intestine adsorption or delivered through the dermal mucosa. Also, it provides an analysis of more invasive solutions that include intracranially injected hydrogels and implanted devices for local drug delivery. Efforts in findi...Continue Reading

References

Mar 7, 1985·Nature·C Masters
Aug 16, 1984·Biochemical and Biophysical Research Communications·G G Glenner, C W Wong
Apr 28, 1999·Journal of Neuropathology and Experimental Neurology·D G DavisW R Markesbery
May 29, 2004·Neurobiology of Aging·Heiko Braak, Kelly Del Tredici
Dec 14, 2004·The New England Journal of Medicine·Stanley FahnUNKNOWN Parkinson Study Group
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·William M Pardridge
Dec 20, 2005·Lancet·Cleusa P FerriUNKNOWN Alzheimer's Disease International
May 23, 2006·Nature Reviews. Neuroscience·Clive Ballard, Robert Howard
Mar 3, 2007·Nature Reviews. Drug Discovery·Christopher J H PorterWilliam N Charman
Jul 20, 2007·The Journal of Pharmacy and Pharmacology·Yashwant GuptaSanjay K Jain
Jun 27, 2008·Neurology·R KatzenschlagerUNKNOWN Parkinson's Disease Research Group of the United Kingdom
Jul 26, 2008·Journal of Biomedical Materials Research. Part a·Jinku KimLichun Lu
Sep 23, 2008·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Karsten UlbrichJörg Kreuter
Nov 11, 2008·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Hiroyuki ItosakaYoshinobu Iwasaki
Dec 6, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Robert A HauserUNKNOWN FIRST-STEP Study Group
Jan 22, 2009·Journal of Pharmaceutical Sciences·Siva Ram Kiran VakaS Narasimha Murthy
Feb 11, 2009·Journal of Neurology, Neurosurgery, and Psychiatry·O L LopezS T Dekosky
Feb 18, 2009·Journal of Alzheimer's Disease : JAD·Simona CapsoniAntonino Cattaneo
Jun 16, 2009·Lancet·Andrew J LeesTamas Revesz
Dec 7, 2010·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·H NazarM Roldo
Mar 5, 2011·Lancet·Clive BallardEmma Jones
Nov 23, 2011·The AAPS Journal·Bruce J Aungst
Dec 24, 2011·Neuroscience Research·Emily R AurandKimberly B Bjugstad
Mar 30, 2012·Biomedical Materials·Malgosia M PakulskaMolly S Shoichet
Nov 6, 2013·Nature Reviews. Neurology·Bryony Jones
Apr 9, 2014·International Journal of Pharmaceutics·Shuai QianZhong Zuo
Jul 17, 2014·The Journal of Pharmacology and Experimental Therapeutics·Joseph A FalconeWilliam A Banks

❮ Previous
Next ❯

Citations

Apr 23, 2020·Frontiers in Bioengineering and Biotechnology·Seyed Zachariah MoradiMohammad Abdollahi
Aug 28, 2021·International Journal of Molecular Sciences·Keelan Jagaran, Moganavelli Singh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cell Aging (Keystone)

This feed focuses on cellular aging with emphasis on the mitochondria, autophagy, and metabolic processes associated with aging and longevity. Here is the latest research on cell aging.

Brain Aging

Here is the latest research on intrinsic and extrinsic factors, as well as pathways and mechanisms that underlie aging in the central nervous system.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.